Company profile

Nuvation Bio

NUVB · NYSE (Two rows for one company, differing only by the 'Inc.' suffix. Both are Nasdaq NUVB. Duplicate company row 1898 ("Nuvation Bio Inc.") merged into this one on 2026-08-06; source: https://ir.nuvationbio.com/)

Share price · NUVB

$6.96+2.75 (+65.32%) 3M

close as of 2026-08-18 · 24h delayed · vol 6.5M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.